The U.S. cancer research ecosystem is vital and interconnected, involving academia, pharmaceutical industries, and funding from various sources. With an annual expenditure exceeding $7.2 billion through the National Cancer Institute, the investments have significantly reduced cancer mortality rates. However, recent funding cuts and instability in various sectors jeopardize this progress. Early-career scientists are leaving academia due to uncertainty, and mid-career researchers are increasingly burdened with securing funds instead of focusing on research. This could halt advancements and drain expertise from crucial research areas.
When one falters, the whole system becomes vulnerable.
Funding delays, political shifts, and instability across sectors have created an environment where basic research into the fundamentals of cancer biology is struggling to keep traction.
Collection
[
|
...
]